source
- FDA pauses enrollment in Biohaven's epilepsy trials after earlier depression trial failureFDA placed a partial clinical hold on Biohaven's Kv7 potassium channel agonist, BHV-7000 (opakalim), halting enrollment of new patients in two late-stage focal epilepsy studies. The pause follows…
- Novartis shareholder urges board overhaul after share plunge tied to trial setbacksA prominent Novartis investor has publicly called for a revamp of the company’s board, arguing that stronger governance is needed after the stock experienced a record decline. The demand was voice…